Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary

Inozyme Pharma

07/05/2024 15:54

* Inozyme Pharma Inc  INZY.OQ  reported a quarterly adjusted
loss
of 38 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -40 cents.  The mean expectation of six analysts for the
quarter was for a loss of 36 cents per share. Wall Street
expected results to range from -39 cents to -30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inozyme Pharma Inc's reported EPS for the quarter was a
loss
of 38 cents​.
    * The company reported a quarterly loss of $23.35 million.
    * Inozyme Pharma Inc shares had fallen by 36.3% this
quarter and
gained 14.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $15.50 

This summary was machine generated from LSEG data May 7 at 02:54
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.36          -0.38          Missed
 Dec. 31 2023      -0.32          -0.33          Missed
 Sep. 30 2023      -0.32          -0.29          Beat
 Jun. 30 2023      -0.43          -0.35          Beat